Real-life data of abiraterone acetate and enzalutamide treatment in post-chemotherapy metastatic castration-resistant prostate cancer in Poland
ConclusionsENZA treatment may be related to more favorable oncological outcomes than ABI treatment in the studied Polish population of patients. A 50% decline in PSA is an indicator of longer TTF and OS. Due to the non-randomized and retrospective nature of the analysis, the current results require prospective validation.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
More News: Abiraterone Acetate | Cancer | Cancer & Oncology | Chemotherapy | Docetaxel | Hormones | Poland Health | Prednisone | Prostate Cancer | Study | Taxotere | Urology & Nephrology